{
  "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5",
  "docSlug": "225408061c3ed04b028031d27cf2467f",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides",
  "authorId": "immix-biopharma",
  "authorName": "ImmixBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 62,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide uses a bar chart to compare hematologic and cardiac response rates across different therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/21",
  "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5",
  "deckJsonHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5.json",
  "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.6,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "chart",
      "text": "response rates in relapsed/refractory AL Amyloidosis",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb0824ce-d33a-42f3-aa6e-6b2c7c4eb915",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.72,
        "y": 0.3
      },
      "kind": "list",
      "text": "NXC-201 Only CAR-T in AL Amyloidosis; NXC-201 100% Overall Response Rate; Cardiac Response exceeds CAEL-101 and Birtamimab; Zero Neurotoxicity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "119ddead-aee6-4851-822f-cfb6aae9aeae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Birtamimab Source: Gertz MA et al. J Clin Oncol. 2016; CAEL-101 source: Edwards CV, et al. Blood. 2021...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a05bca21-bd33-4e4a-a164-a5dda8298319",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 - First CAR-T in AL Amyloidosis, a $6 billion market by 2025",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf456fb9-c054-432b-bdac-4f283c94cea5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 34,
      "from": 15,
      "beatId": "167b9d6c-4f69-438b-b991-0f1839680299",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 20,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5",
      "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.",
      "position": 0,
      "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 33,
      "from": 21,
      "name": "David Goliath",
      "slug": "16-david-goliath",
      "bestFor": "Startups, disruptive innovation, competitive displacement",
      "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18",
      "evidence": "The document presents clinical data and comparisons to existing therapies.",
      "position": 1,
      "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?",
      "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple",
      "confidence": 0.7,
      "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}